Evidence map›Paper›PMID 38804889›Full record

ArticleImmunity, inflammation and disease2024

Prior COVID-19 infection among newly diagnosed tuberculosis patients in a tertiary care center in Tehran: A case-control study.

Kiavash Semnani, Marjan Sohrabi, Parvaneh Ebrahimi Alavijeh, SeyedAhmad SeyedAlinaghi, Shirin Esmaeili, Farzin Halabchi, Zahra Alizadeh, Amir Salami, Arezoo Salami Khaneshan

Abstract read
In one paragraph

Article in Immunity, inflammation and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kiavash SemnaniTehran University of Medical Sciences School of Medicine, Tehran, Iran.
Marjan SohrabiDepartment of Infectious Diseases, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tohid Squre, Tehran, Iran.
Parvaneh Ebrahimi AlavijehDepartment of Infectious Diseases, Tehran University of Medical Sciences, Arash Women's Hospital, Tehran, Iran.
SeyedAhmad SeyedAlinaghiIranian Research Center for HIV/AIDS, Tehran University of Medical Sciences, Iranian Institute for Reduction of High Risk Behaviors, Tehran, Iran.
Shirin EsmaeiliTehran University of Medical Sciences School of Medicine, Tehran, Iran.
Farzin HalabchiDepartment of Sports and Exercise Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Zahra AlizadehDepartment of Sports and Exercise Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Amir SalamiStudent Research Committee, Iran University of Medical Sciences School of Medicine, Hemmat Hwy, Tehran, Iran.
Arezoo Salami KhaneshanDepartment of Infectious Diseases, Tehran University of Medical Sciences, Imam Khomeini Hospital Complex, Tohid Squre, Tehran, Iran.ORCID 0000-0001-8349-9625

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo assess the risk of developing pulmonary tuberculosis (TB) in accordance with prior history of COVID-19 infection.

backgroundSince the advent of the COVID-19 pandemic much discussion has been had on the possible role it might play on global efforts to combat TB; most, focusing on the pandemic's impact on health care systems' capabilities to manage TB cases. Mechanisms have also been proposed by which the COVID-19 infection may directly affect individuals' chance of developing TB infection. Cases have been reported with a history of COVID-19 infection preceding a diagnosis of TB, evidencing its possible role as a risk factor for the disease.

methodsA case-control study was conducted enrolling patients diagnosed with pulmonary TB in the absence of major risk factors previous history of TB, (HIV) human immunodeficiency virus infection), end-stage renal disease, organ transplants, and use of immunosuppressive agents) for developing TB. Each patient was age and sex matched with one healthy control. Data regarding prior COVID-19 infection, diabetes, and smoking status as well as the use of corticosteroids and Tocilizumab for the treatment of COVID-19 infection was obtained. Bivariate analysis was conducted and variables with a likely association with TB status were entered in a multivariate model.

resultsBivariate analysis demonstrated a significant relationship between prior COVID-19 infection and TB (95% confidence interval = 1.1-22.8, odds ratio [OR] = 5). Among other variables the severity of COVID-19 infection was found to have a likely association with TB status (p = .125). In a multivariate model, prior COVID-19 infection per se, was not found to be significantly associated with TB (p = .12, OR = 4.5).

conclusionsThere seems to be an association between prior history of COVID-19 and a future diagnosis of TB partially linked to the severity of disease. The findings of the current study may serve as a basis for further studies to determine the need for and efficacy of measures to follow-up COVID-19 patients at an increased risk for developing TB.

Indexed as

COVID-19SARS-CoV-2Tertiary Care CentersTuberculosis, PulmonaryAdultAgedCase-Control StudiesFemaleHumansIranMaleMiddle AgedRisk FactorscorticosteroidCOVID‐19preventionpulmonaryreactivationriskTocilizumabtuberculosis

Identifiers

PMID38804889
PMCPMC11131933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.